Phase 2 Study of the Efficacy and Safety of ORC-13661 for the Prevention of Ototoxicity in Patients Receiving Intravenous Amikacin for Treatment of Non-Tuberculous Mycobacterium Infection
ORC-13661预防静脉阿米卡星治疗非结核分枝杆菌感染患者耳毒性的有效性和安全性的2期研究
基本信息
- 批准号:10426862
- 负责人:
- 金额:$ 65.79万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-19 至 2027-07-31
- 项目状态:未结题
- 来源:
- 关键词:AdultAdverse eventAftercareAirAmikacinAminoglycoside AntibioticsAminoglycosidesAnimal ModelAntibiotic TherapyAntibioticsAuditory ThresholdAzithromycinBronchiectasisCanis familiarisChemicalsChronicChronic DiseaseClarithromycinClinicalCochleaCommunicable DiseasesControl AnimalData ReportingDeteriorationDiagnosisDiseaseDisease ProgressionDoseDouble-Blind MethodDrug DesignDrug ExposureDrug KineticsElderlyElectrocardiogramEquilibriumEquipment and supply inventoriesEvaluationExposure toFDA approvedFrequenciesGenus MycobacteriumGoalsGram-Negative BacteriaGuidelinesHair CellsHalf-LifeHealthHearingHearing ProtectionHuman VolunteersIn VitroIntravenousLaboratoriesLaboratory FindingLegal patentLifeLungMeasurableMeasuresMetabolicMindMulti-Institutional Clinical TrialMusMycobacterium InfectionsNeonatalOralOral AdministrationOrgan of CortiPatientsPersonsPharmaceutical PreparationsPharmacotherapyPhasePlacebo ControlPlasmaPreventionPublishingQuality of lifeRandomizedRattusResearchRifampinSafetySensorineural Hearing LossSensory HairSerious Adverse EventSwimmingSymptomsTestingTherapeutic IndexTimeTinnitusToxic effectToxicologyTreatment ProtocolsUnited StatesUniversitiesVertigoWashingtonWomanWorkZebrafishaminoglycoside-induced ototoxicityawakebactericidebonechronic infectionclinically relevanteffective therapyeffectiveness evaluationefficacy evaluationefficacy studyexperimental studyhealthy volunteerhearing impairmentin vivoindexingmenneonatal micenon-tuberculosis mycobacterianovelnovel therapeuticsototoxicityovertreatmentphase 1 testingphase 2 studypre-clinicalpreventprevent hearing lossprimary endpointprogramsresponsesafety studysecondary endpointside effectsmall moleculespeech in noisetooltreatment duration
项目摘要
PROJECT SUMMARY
ORC-13661 is a new chemical entity being developed to prevent hearing loss in patients exposed to
aminoglycoside antibiotics (AGs). AGs are an important class of broad spectrum antibiotics especially
effective against gram-negative bacteria and Mycobacteria. Unfortunately, as many as 20% of patients
administered parenteral AGs for over 5 days suffer permanent, measurable hearing loss, as do upwards of
60% of patients on long term therapy. Largely because of the ototoxic side effects, AGs are currently
administered only for life threatening situations or where they are the only effective treatment. At this time
there are no FDA approved drugs that have been shown to prevent any form of sensorineural hearing loss.
Preventing AG-induced hearing loss would be of enormous benefit patients currently being treated with AGs. It
would also allow this inexpensive and effective but underused class of antibiotics to be used more routinely.
Oral ORC-13661was developed from a small molecule screen aimed finding a way to mitigate AG-induced hair
cell toxicity. It is robustly effective at preventing hearing loss in rats treated with prolonged high dose AGs.
ORC-13661 has completed nonclinical evaluation and Phase 1 testing in normal healthy volunteers.
Pulmonary and disseminated non-tuberculous Mycobacteria (NTM) infections are chronic infectious diseases
that develop progressively over time, and require prolonged parenteral AG therapy to achieve control or a cure.
Current guidelines recommend parenteral aminoglycoside (AG) therapy, usually a 90 day course of amikacin,
for patients with severe manifestations of the disease, particularly bronchiectasis.
We propose a randomized, double-blind, placebo-controlled, multicenter, phase 2 study of ORC-13661
administered orally in conjunction with intravenously administered amikacin to patients with severe NTM
infections. The goal of this to evaluate the efficacy of ORC-13661 for mitigation or prevention of ototoxicity.
Primary and secondary endpoints are changes in between baseline measures if hearing thresholds and
hearing in noise taken prior to drug treatment and after treatment is discontinued in groups of patients treated
with amikacin alone or with amikacin plus ORC-13661. Additional evaluations will changes in patient perceived
hearing and balance health and the safety and tolerability of ORC-13661 in patients with NTM as assessed by
AEs, clinical laboratory findings, vital signs, and electrocardiogram (ECG).
项目总结
ORC-13661是一种正在开发的新化学物质,用于预防暴露于辐射的患者的听力损失
氨基糖苷类抗生素(AGs)。Ags是一类重要的广谱抗生素。
对革兰氏阴性细菌和分枝杆菌有效。不幸的是,多达20%的患者
静脉注射超过5天的AGG会导致永久性的、可测量的听力损失,
60%的患者接受长期治疗。很大程度上是因为耳毒性副作用,AGG目前
仅在危及生命或是唯一有效治疗方法的情况下使用。在这个时候
目前还没有FDA批准的药物被证明可以预防任何形式的感觉神经性听力损失。
预防AG引起的听力损失将对目前正在接受AG治疗的患者有极大的好处。它
这也将使这种廉价有效但未得到充分利用的抗生素能够更常规地使用。
口服ORC-13661是从一种小分子筛选器开发出来的,目的是找到一种减轻AG诱导的头发的方法
细胞毒性。对长期服用大剂量银杏叶提取物所致大鼠听力损失有明显的预防作用。
ORC-13661已经在正常健康志愿者身上完成了非临床评估和第一阶段测试。
肺部和播散性非结核分支杆菌(NTM)感染是慢性传染病。
随着时间的推移逐渐发展,需要长期的AG非肠道治疗才能达到控制或治愈的目的。
目前的指南推荐氨基糖苷(AG)肠外治疗,通常为90天的阿米卡星疗程,
适用于有严重症状的患者,尤其是支气管扩张症患者。
我们提出了一项随机、双盲、安慰剂对照、多中心、ORC-13661的2期研究
口服联合静脉注射阿米卡星治疗重症NTM
感染。其目的是评估ORC-13661在减轻或预防耳毒性方面的疗效。
主要和次要终点是基线测量之间的变化,如果听力阈值和
在药物治疗前和治疗后,接受治疗的患者组停止在噪音中听力
阿米卡星单独或与阿米卡星和ORC-13661合用。额外的评估将改变患者感知的
听力和平衡健康以及ORC-13661在非脑膜瘤患者中的安全性和耐受性
临床实验室检查、生命体征和心电图检查。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Edwin W Rubel其他文献
Edwin W Rubel的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Edwin W Rubel', 18)}}的其他基金
Phase 2 Study of the Efficacy and Safety of ORC-13661 for the Prevention of Ototoxicity in Patients Receiving Intravenous Amikacin for Treatment of Non-Tuberculous Mycobacterium Infection
ORC-13661预防静脉阿米卡星治疗非结核分枝杆菌感染患者耳毒性的有效性和安全性的2期研究
- 批准号:
10706468 - 财政年份:2022
- 资助金额:
$ 65.79万 - 项目类别:
ROLE OF THE INNATE IMMUNE SYSTEM IN THE SURVIVAL OF AUDITORY NEURONS
先天免疫系统在听觉神经元生存中的作用
- 批准号:
10119786 - 财政年份:2017
- 资助金额:
$ 65.79万 - 项目类别:
Core Center--NIDCD Research Core Center P30
核心中心--NIDCD研究核心中心P30
- 批准号:
7901262 - 财政年份:2009
- 资助金额:
$ 65.79万 - 项目类别:
Core Center--NIDCD Research Core Center P30
核心中心--NIDCD研究核心中心P30
- 批准号:
6953304 - 财政年份:2000
- 资助金额:
$ 65.79万 - 项目类别:
Core Center - NIDCD Research Core Center P30
核心中心 - NIDCD 研究核心中心 P30
- 批准号:
8526210 - 财政年份:2000
- 资助金额:
$ 65.79万 - 项目类别:
相似海外基金
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10707830 - 财政年份:2023
- 资助金额:
$ 65.79万 - 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
- 批准号:
479728 - 财政年份:2023
- 资助金额:
$ 65.79万 - 项目类别:
Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
- 批准号:
10884567 - 财政年份:2023
- 资助金额:
$ 65.79万 - 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
- 批准号:
10751964 - 财政年份:2023
- 资助金额:
$ 65.79万 - 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
- 批准号:
486321 - 财政年份:2022
- 资助金额:
$ 65.79万 - 项目类别:
Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10676786 - 财政年份:2022
- 资助金额:
$ 65.79万 - 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10440970 - 财政年份:2022
- 资助金额:
$ 65.79万 - 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
- 批准号:
10642998 - 财政年份:2022
- 资助金额:
$ 65.79万 - 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10482465 - 财政年份:2022
- 资助金额:
$ 65.79万 - 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
- 批准号:
10191053 - 财政年份:2020
- 资助金额:
$ 65.79万 - 项目类别: